B. Riley Predicts Electromed’s Q3 Earnings (NYSE:ELMD)

Electromed, Inc. (NYSE:ELMD) – Research analysts at B. Riley issued their Q3 2025 EPS estimates for shares of Electromed in a research note issued on Wednesday, February 19th. B. Riley analyst K. Bauser anticipates that the company will earn $0.19 per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. B. Riley also issued estimates for Electromed’s Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.31 EPS, FY2026 earnings at $1.00 EPS and FY2027 earnings at $1.16 EPS.

Separately, StockNews.com downgraded shares of Electromed from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Electromed Stock Down 0.8 %

Electromed stock opened at $26.76 on Monday. The firm has a market cap of $228.99 million, a PE ratio of 35.68 and a beta of 0.33. Electromed has a 52-week low of $13.74 and a 52-week high of $35.56. The company’s 50 day moving average is $31.35 and its two-hundred day moving average is $25.58.

Insider Buying and Selling at Electromed

In related news, Director Kathleen Skarvan sold 8,640 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $32.25, for a total value of $278,640.00. Following the transaction, the director now directly owns 71,576 shares of the company’s stock, valued at $2,308,326. This trade represents a 10.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Andrew Summers sold 50,751 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.30, for a total transaction of $1,385,502.30. Following the completion of the transaction, the director now directly owns 65,714 shares in the company, valued at $1,793,992.20. This trade represents a 43.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 163,812 shares of company stock valued at $4,728,773. Insiders own 14.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new position in shares of Electromed in the 4th quarter valued at $37,000. IFP Advisors Inc purchased a new position in shares of Electromed in the 4th quarter valued at $59,000. Quantbot Technologies LP purchased a new position in shares of Electromed in the 4th quarter valued at $99,000. Bank of America Corp DE grew its position in shares of Electromed by 179.2% in the 4th quarter. Bank of America Corp DE now owns 4,004 shares of the company’s stock valued at $118,000 after buying an additional 2,570 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Electromed in the 4th quarter valued at $119,000. 40.82% of the stock is owned by hedge funds and other institutional investors.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.